Characteristics | Number of participants and percentage or mean and standard deviation | |
Location | Niterói | 45 (33.83%) |
| Petrópolis | 88 (66.17%) |
Age | Less than 60 years old | 63 (47.37%) |
| 60 years old or older | 70 (52.63%) |
Education level | Up to incomplete primary school | 60 (45.11%) |
| At least completed primary school | 73 (54.89%) |
Nocturia 1 | No urination | 39 (29.32%) |
| One or more urinations | 94 (70.68%) |
Nocturia 2 | Up to one urination | 58 (43.61%) |
| Two or more urinations | 75 (56.39%) |
Stress urinary incontinence | No | 110 (82.71%) |
| Yes | 23 (17.29%) |
Urgency urinary incontinence | No | 115 (86.47%) |
| Yes | 18 (13.53%) |
Mixed urinary incontinence | No | 59 (44.36%) |
| Yes | 74 (55.64%) |
Overactive bladder syndrome | No | 35 (26.32%) |
| Yes | 98 (73.68%) |
Hesitation | No | 118 (88.72%) |
| Yes | 15 (11.28%) |
Slow stream | No | 110 (82.71%) |
| Yes | 23 (17.29%) |
Feeling of incomplete bladder emptying | No | 59 (44.36%) |
| Yes | 74 (55.64%) |
Post-voiding incontinence | No | 91 (68.42%) |
| Yes | 42 (31.58%) |
Pelvic organ prolapse (symptom) | No | 91 (68.42%) |
| Yes | 42 (31.58%) |
Anterior vaginal wall prolapse | Up to stage II | 119 (89.47%) |
| Stage III or IV | 14 (10.53%) |
Posterior vaginal wall prolapse | Up to stage II | 130 (97.74%) |
| Stage III or IV | 3 (2.26%) |
Apical prolapse | Up to stage II | 130 (97.74%) |
| Stage III or IV | 3 (2.26%) |
Fecal incontinence | No | 124 (93.23%) |
| Yes | 9 (6.77%) |
Constipation (Bristol stool scale) | No | 107 (80.45%) |
| Yes | 26 (19.55%) |
Constipation (bowel movement frequency) | No | 105 (78.95%) |
| Yes | 28 (21.05%) |
Recurrent urinary tract infection | No | 116 (87.22%) |
| Yes | 17 (12.78%) |
Systemic arterial hypertension | No | 54 (40.60%) |
| Yes | 79 (59.40%) |
Diabetes mellitus | No | 93 (69.92%) |
| Yes | 40 (30.08%) |
Congestive heart failure | No | 131 (98.50%) |
| Yes | 2 (1.50%) |
Chronic kidney disease | No | 130 (97.74%) |
| Yes | 3 (2.26%) |
Chronic venous insufficiency | No | 90 (67.67%) |
| Yes | 43 (32.33%) |
Depression/Anxiety | No | 115 (86.47%) |
| Yes | 18 (13.53%) |
Number of comorbidities | Up to two | 25 (33.30%) |
| Three or more | 107 (66.70%) |
Antidepressant | No | 107 (80.45%) |
| Yes | 26 (19.55%) |
Diuretic | No | 93 (69.92%) |
| Yes | 40 (30.08%) |
Calcium channel blocker | No | 110 (82.71%) |
| Yes | 23 (17.29%) |
Benzodiazepine | No | 119 (89.47%) |
| Yes | 14 (10.53%) |
Angiotensin II receptor blocker | No | 73 (54.89%) |
| Yes | 60 (45.11%) |
Beta-blocker | No | 111 (83.46%) |
| Yes | 22 (16.54%) |
Hypoglycemic agent | No | 94 (70.68%) |
| Yes | 39 (29.32%) |
Insulin | No | 126 (94.74%) |
| Yes | 7 (5.26%) |
Angiotensin-converting enzyme inhibitor | No | 126 (94.74%) |
| Yes | 7 (5.26%) |
Polypharmacy | No | 91 (68.42%) |
| Yes | 42 (31.58%) |
Caffeine (mg/day) |
| 163.1 ± 77.8 |
Tobacco (packs/year) |
| 4.4 ± 13.5 |
Body mass index (BMI)a | Normal | 20 (15.15%) |
| Obesity | 52 (39.39%) |
| Overweight | 60 (45.46%) |
Risk of obstructive sleep apnea | Low | 54 (40.60%) |
| Intermediate/High | 79 (59.40%) |